Funding for this research was provided by:
Received: 18 October 2017
Accepted: 23 May 2018
First Online: 16 July 2018
Ethics approval and consent to participate
: This was an observational retrospective study using anonymised data from CPRD, which holds ethical approval for observational studies. The Independent Scientific Advisory Committee for Medicines and Healthcare Products Regulatory Agency (protocol 16_045R) approved this study.
: Not applicable.
: JM, PC, PF and NH are employees of AstraZeneca.KK has received honoraria and research support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche and Sanofi.JW has received honoraria from Astellas, AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Orexigen, and Sanofi; undertaken institutional consultancy with AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, and Orexigen; and received institutional grants from Takeda, Novo Nordisk and AstraZeneca.LS is supported by a senior clinical fellowship from The Wellcome Trust, UK.TG and RF report no conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.